GoodRx (NASDAQ:GDRX) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

GoodRx (NASDAQ:GDRXGet Rating) announced its quarterly earnings data on Monday. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.02, MarketWatch Earnings reports. GoodRx had a positive return on equity of 0.06% and a negative net margin of 3.39%. The company had revenue of $203.30 million for the quarter, compared to analyst estimates of $200.61 million. During the same quarter last year, the firm earned ($0.01) EPS. GoodRx’s revenue for the quarter was up 26.7% compared to the same quarter last year. GoodRx updated its Q2 2022 guidance to EPS.

GDRX stock opened at $10.75 on Tuesday. The company has a debt-to-equity ratio of 0.79, a current ratio of 13.42 and a quick ratio of 13.42. The stock has a market capitalization of $4.31 billion, a P/E ratio of -153.55, a P/E/G ratio of 4.42 and a beta of 0.29. The business has a 50-day moving average of $16.74 and a 200-day moving average of $27.69. GoodRx has a fifty-two week low of $10.65 and a fifty-two week high of $48.05.

A number of hedge funds and other institutional investors have recently modified their holdings of GDRX. Bell Rock Capital LLC acquired a new position in GoodRx during the fourth quarter valued at approximately $242,000. Kingsview Wealth Management LLC boosted its position in GoodRx by 48.6% during the fourth quarter. Kingsview Wealth Management LLC now owns 8,346 shares of the company’s stock valued at $273,000 after purchasing an additional 2,730 shares during the last quarter. Advisor Group Holdings Inc. raised its stake in GoodRx by 17.6% in the first quarter. Advisor Group Holdings Inc. now owns 28,454 shares of the company’s stock valued at $414,000 after buying an additional 4,265 shares during the period. Citigroup Inc. boosted its stake in shares of GoodRx by 61.3% during the 4th quarter. Citigroup Inc. now owns 19,786 shares of the company’s stock worth $647,000 after acquiring an additional 7,518 shares during the period. Finally, Parametric Portfolio Associates LLC acquired a new stake in GoodRx during the 4th quarter worth approximately $1,593,000. 52.60% of the stock is owned by hedge funds and other institutional investors.

Several analysts have recently weighed in on GDRX shares. Barclays decreased their price objective on GoodRx from $35.00 to $28.00 and set an “overweight” rating on the stock in a report on Tuesday, March 8th. Robert W. Baird boosted their price target on GoodRx from $17.00 to $23.00 in a research note on Tuesday, April 5th. SVB Leerink lowered GoodRx from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $33.00 to $10.00 in a research note on Tuesday. Evercore ISI lowered GoodRx from an “outperform” rating to an “inline” rating and decreased their price target for the company from $28.00 to $12.00 in a research note on Tuesday. Finally, Credit Suisse Group decreased their price target on GoodRx from $27.00 to $22.00 and set a “neutral” rating on the stock in a research note on Thursday, March 17th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and seven have given a buy rating to the stock. According to MarketBeat, GoodRx presently has an average rating of “Hold” and a consensus target price of $26.56.

GoodRx Company Profile (Get Rating)

GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.

Featured Stories

Earnings History for GoodRx (NASDAQ:GDRX)

Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.